NCT06509009 2025-09-19
Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
Clinical Trials
4 trialsNCT07070479 2025-09-18
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
Sun Yat-sen University
Phase 2 Recruiting
NCT06912711 2025-05-21
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT04456322 2025-05-14
Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Active not recruiting